Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q96E22
UPID:
NGBR_HUMAN
Alternative names:
Cis-prenyltransferase subunit NgBR; Nogo-B receptor; Nuclear undecaprenyl pyrophosphate synthase 1 homolog
Alternative UPACC:
Q96E22; B2RWQ4; O00251
Background:
Dehydrodolichyl diphosphate synthase complex subunit NUS1, also known as Cis-prenyltransferase subunit NgBR, plays a pivotal role in the biosynthesis of dolichol phosphate, a critical component for protein glycosylation in the endoplasmic reticulum. This process is essential for the proper folding and function of many proteins, highlighting the importance of NUS1 in cellular operations.
Therapeutic significance:
NUS1 is linked to congenital disorders of glycosylation and intellectual developmental disorders with seizures, underscoring its potential as a target for therapeutic intervention. Understanding the role of NUS1 could open doors to potential therapeutic strategies.